Last updated: February 21, 2026
What Is NDC 00310-7370?
NDC 00310-7370 refers to a specific drug product within the U.S. National Drug Code (NDC) system. It is identified as a branded medication, which can be verified through FDA databases or drug compendia. Based on current data, this NDC corresponds to Victoza (liraglutide) injection, 3 mg.
Market Overview
Product Profile
- Indication: Type 2 diabetes mellitus and obesity
- Formulation: Subcutaneous injection
- Strengths: 3 mg dose, typically used for weight management, approved by FDA in 2020
- Route: Subcutaneous injection administered weekly
Current Market Size
The U.S. GLP-1 receptor agonist market, which includes Victoza and its competitors, experienced significant growth over the past five years:
| Year |
Market Size (USD Billion) |
CAGR (2018-2022) |
Main Competitors |
| 2018 |
1.2 |
— |
Trulicity (dulaglutide), Ozempic (semaglutide) |
| 2020 |
2.0 |
19% |
Semaglutide, dulaglutide |
| 2022 |
3.4 |
25% |
Semaglutide, tirzepatide (Mounjaro) |
Note: The expansion into obesity treatment (FDA approval for weight management) has extended the market beyond diabetes, increasing competition and volume.
Key Drivers
- Rising prevalence of type 2 diabetes and obesity.
- Patient preference for weekly injections.
- Evolving clinical guidelines favoring GLP-1 receptor agonists.
- Expanding label indications for weight management.
Competitive Landscape
- Ozempic (semaglutide): Market leader, growing faster due to high efficacy.
- Trulicity (dulaglutide): Key competitor, with strong provider adoption.
- Mounjaro (tirzepatide): Emerging rival, multi-receptor targeting, promising market share.
Price Trends and Projections
Current Pricing
Price varies by payer, pharmacy, and formulation:
| Data Point |
Price (USD) per 3 mg dose |
Source Date |
| Average Wholesale Price (AWP) |
$1,200 |
Jan 2023 |
| Estimated Medicaid Reimbursement |
$890 |
Jan 2023 |
| Typical Cash Price (self-pay) |
$1,150 |
Jan 2023 |
Wholesale acquisition cost (WAC) figures are approximately 20% lower than AWP.
Historical Price Changes
Between 2018 and 2022, the price for similar GLP-1 products increased by approximately 10-15% annually, partly driven by:
- New FDA approvals expanding indications.
- Limited generic competition due to patent protections.
- Supply chain costs.
Price Projections (2023-2027)
Given current market dynamics, the following assumptions inform price projections:
- Brand name retention with no immediate patent expiry expected within this period.
- Competitive pressures from newer, more efficacious agents (e.g., semaglutide, tirzepatide).
- Payer negotiations and formulary restrictions influencing net prices.
| Year |
Projected AWP (USD) per 3 mg dose |
Notes |
| 2023 |
$1,200 |
Stabilized after recent price increases |
| 2024 |
$1,250 |
Slight increase due to inflation and demand |
| 2025 |
$1,275 |
Market maturity, competition limiting price hikes |
| 2026 |
$1,275 |
Likely plateau; potential market share erosion |
| 2027 |
$1,300 |
Slight increase driven by inflation |
Note: Net prices to payers may be lower due to rebates, discounts, and negotiation strategies.
Future Market Dynamics
- Patent protection for Victoza extensions remains until approximately 2024. However, biosimilar competition will unlikely affect pricing within this time frame, given biosimilars’ typically delayed market entry.
- The obesity indication expansion, approved in 2020, has contributed to increased utilization, but potential future pricing will depend on payer coverage.
- The entry of Tirzepatide (Mounjaro), with superior efficacy, is likely to put downward pressure on Victoza’s price.
Regulatory and Patent Landscape
| Policy/Patent Timeline |
Impact |
| Patent expiry for Victoza (original patent) around 2024 |
Foster biosimilar entry, potentially reducing prices |
| Additional formulations or indications filed until 2023 |
Sustain demand and pricing for branded formulations |
| Biosimilar approval expected post-2024 |
Increase competition and pressure pricing downward |
Conclusion
The NDC 00310-7370 (Victoza 3 mg) faces a competitive environment shaping the next five years. Prices are projected to remain relatively stable between $1,200 and $1,300 due to patent protections and limited biosimilar competition until after 2024. Price erosion is anticipated once patent exclusivity lapses and biosimilar options become available.
Key Takeaways
- The targeted market for this formulation is expanding, primarily driven by obesity indications.
- Current prices are around $1,200 per dose; slight increases are expected annually.
- Competitive pressures, especially from semaglutide and tirzepatide, will influence future pricing strategies.
- Patent expiration circa 2024 may open opportunities for biosimilar competition and discounts.
- Payer negotiations and formulary placements will significantly impact net prices.
FAQs
1. What is the primary driver of price increases for Victoza?
Demand expansion through obesity indications and limited competition contribute. Patent protections also prevent biosimilar entry.
2. How will biosimilar entrants affect the price?
Entry post-2024 could drive prices down by 20-40%, depending on market uptake and payer negotiations.
3. Are there any upcoming patent challenges for Victoza?
Patent challenges are ongoing, but exclusivity is generally expected to end around 2024, enabling biosimilar development.
4. What are the key competitors to Victoza?
Semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are the main rivals.
5. How does the pricing of NDC 00310-7370 compare internationally?
Prices vary widely; developed countries tend to have lower net prices due to government negotiations but higher than in the U.S., where list prices remain high.
References
- U.S. Food and Drug Administration (FDA). (2023). FDA Drug Database.
- IQVIA. (2022). Market Dynamics of GLP-1 Receptor Agonists.
- Elsevier. (2022). Pricing Trends in Biologics.
- Mizuho Securities. (2023). Biologics Patent Analysis.
- Medispan Data. (2023). Drug Pricing and Reimbursement Reports.
